Discovering a Breakthrough: Gilead’s Long-Standing Commitment to Helping Change the Course of HIV
In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited. He was 12 years into his virology research career at Gilead and the first daily single tablet regimen for HIV treatment was still awaiting approval. Treatment options for people living with HIV at the time were a raft of daily medications that often carried intolerable side-effects, or the virus became resistant to the
